TrialVirology journal2025

Outcomes of switching from protease inhibitor-based antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with nucleos(t)ide analogue resistance- a phase IV randomised, open-label study (PIBIK study).

Collins Iwuji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.